These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3099802)

  • 1. Cytotoxic effect of serum on fibroblasts in one case of normolipidemic plane xanthoma and myeloma IgG lambda.
    Bérard M; Antonucci M; Beaumont JL
    Atherosclerosis; 1986 Nov; 62(2):111-5. PubMed ID: 3099802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Normolipemic plane xanthomas and IgGk myeloma with anti-lipoprotein activity. Apropos of a case. Review of the literature].
    Doutre MS; Conri C; Beylot C; Fleury B; Chapoulard H; Bioulac P
    Dermatologica; 1985; 170(4):157-64. PubMed ID: 3922816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin-bound lipoproteins (Ig-Lp) as markers of familial hypercholesterolemia, xanthomatosis and atherosclerosis.
    Beaumont JL; Doucet F; Vivier P; Antonucci M
    Atherosclerosis; 1988 Dec; 74(3):191-201. PubMed ID: 3240331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro interaction of LDL, anti-lipoprotein IgA and human fibroblasts.
    Baudet MF; Dachet C; Beaumont JL
    Biomedicine; 1978 Oct; 29(6):217-20. PubMed ID: 216434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IgG kappa/IgA lambda biclonal gammopathy. Demonstration of the involvement of 2 different plasma-cell clones using anti-idiotypic antibodies].
    Musto P; Bodenizza C; Melillo L; Carotenuto M
    Recenti Prog Med; 1986 Mar; 77(3):142-6. PubMed ID: 3086951
    [No Abstract]   [Full Text] [Related]  

  • 6. [Diffuse normolipidemic plane xanthomatosis and monoclonal dysglobulinemia. A case with anti-lipoprotein activity of monoclonal immunoglobulin and hypocomplementemia].
    Meunier P; Gorin I; Delmer A; Escande JP
    Ann Dermatol Venereol; 1996; 123(2):93-5. PubMed ID: 8761759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical pemphigus associated with monoclonal IgA gammopathy.
    Miyagawa S; Hashimoto T; Ohno H; Nakagawa A; Watanabe K; Nishikawa T; Shirai T
    J Am Acad Dermatol; 1995 Feb; 32(2 Pt 2):352-7. PubMed ID: 7829739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous xanthoma in association with paraproteinemia in the absence of hyperlipidemia.
    Feingold KR; Castro GR; Ishikawa Y; Fielding PE; Fielding CJ
    J Clin Invest; 1989 Mar; 83(3):796-802. PubMed ID: 2921322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The production of antibody-dependent cellular cytotoxicity by immune complexes in systemic lupus erythematosus.
    Penning CA; Hughes P; Rowell NR
    J Clin Lab Immunol; 1984 Mar; 13(3):123-7. PubMed ID: 6716450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diclonal gammopathy (IgG kappa, IgA lambda) with nephrotic syndrome terminating into IgA lambda myeloma after three years--report of a case].
    Shigemi H; Murakami S; Oku N; Itoh K; Fujita N; Nakanishi S; Shimazaki C; Inoue D; Takahashi H; Nakagawa M
    Rinsho Ketsueki; 1990 Feb; 31(2):209-13. PubMed ID: 2109804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of cryoglobulins as lipoprotein-autoantibody immune complexes and antigenic determinants against antilipoprotein autoantibody.
    Kodama H
    Clin Exp Immunol; 1977 Jun; 28(3):437-44. PubMed ID: 70290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
    Delgado Alves J; Kumar S; Isenberg DA
    Rheumatology (Oxford); 2003 Jul; 42(7):893-9. PubMed ID: 12730551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of benign monoclonal gammopathy and smouldering multiple myeloma from frank myeloma.
    Shimizu K; Ohnishi K; Kunii A
    Clin Exp Immunol; 1982 Dec; 50(3):596-600. PubMed ID: 6819908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Normolipemic plane xanthomas and IgG-k multiple myeloma. Description of a clinical case].
    Piccinno R; Menni S; Cavicchini S; Gianotti R
    G Ital Dermatol Venereol; 1990 Oct; 125(10):449-51. PubMed ID: 2127922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma with monoclonal IgG and IgD of lambda type exhibiting, under treatment, a shift from mainly IgG to mainly IgD.
    Gallart T; Bladé J; Martínez-Quesada J; Sierra J; Rozman C; Vives J
    Immunology; 1985 May; 55(1):45-57. PubMed ID: 3922877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgGs containing light chains of the λ- and κ- type and of all subclasses (IgG1-IgG4) from the sera of patients with systemic lupus erythematosus hydrolyze myelin basic protein.
    Bezuglova AM; Konenkova LP; Buneva VN; Nevinsky GA
    Int Immunol; 2012 Dec; 24(12):759-70. PubMed ID: 22899672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The frequency distribution of heavy chain classes and light chain types of 1,000 monoclonal immunoglobulins.
    Creyssel R; Gibaud A; Cordier JF; Boissel JP
    Biomedicine; 1975 Jan; 22(1):41-8. PubMed ID: 810190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plane xanthoma, chronic myelomonocytic leukemia, monoclonal gammapathy and anti-lipoprotein activity].
    Callot C; Cosnes A; Wechsler J; Beaumont JL; Castelneau JP; Intrator ; Najman A; Revuz J
    Ann Dermatol Venereol; 1993; 120(11):798-9. PubMed ID: 8210120
    [No Abstract]   [Full Text] [Related]  

  • 19. Index of light kappa/lambda and lambda/kappa chains in monoclonal gammopathies.
    Tichý M; Hrncír Z
    Neoplasma; 1990; 37(1):55-9. PubMed ID: 2108394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T lymphocyte interaction with immunoglobulin G antibody in systemic lupus erythematosus.
    Okudaira K; Searles RP; Tanimoto K; Horiuchi Y; Williams RC
    J Clin Invest; 1982 Apr; 69(4):1026-38. PubMed ID: 6978891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.